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Abstract 
It has been recently reported that 5-hydroxytryptaminc (5-HT) increases force of contraction in atrial tissue but not in 
ventricular tissue. In the present study with trabeculae obtained from non-diseased human hearts, we investigated whether this 
difference in the contractile responses is specific for 5-HT or is also observed for other substances: calcitonin gene-rclatcd 
peptide (CGRP), angiotensin II, adenosine, somatostatin and acetylcholine. CGRP (10- 9 to 10 7 M) and angiotensin II (10 ~ to 
10 5 M) caused concentration-dependent increases in force of contraction in atrial trabeculae (up to 36 _+ 8% and 42 + 8% of 
the response to 10 -5 M noradrenaline, respectively). Similar to 5-HT, no effects were observed with CGRP and angiotcnsin II in 
ventricular trabeculae. Adenosine (10 s to 10 -5 M) and somatostatin (10 ~ to 10 ~ M) caused concentration-dependent 
negative inotropic effects on baseline atrial contractility ( -54  _+ 17% and -51  _+ 25%, respectively), but no response was found 
on baseline ventricular contractility. Adenosine, but not somatostatin, reduced force of contraction after pre-stimulation with 
10 5 M noradrenaline in atrial tissue and, to a lesser extent, in ventricular tissue. Acetylcholine xhibited a biphasic 
concentration-response curve in the atrial tissue, consisting of an initial negative inotropic response (10 '~ to 10 v M, from 
120 +_ 41 mg at baseline to 48 + 16 mg at 10 7 M), followed by a positive inotropic response (10 -6 to 10 .3 M, from 48 +_ 16 mg 
at 10 -7  M to 77 + 15 rag). On the baseline ventricular force of contraction, acctylcholine (10 -9 to 10 -4 M) induced only a 
positive inotropic effect, starting at 10 9 M (from 252 _+ 65 mg at baseline to 353 + 71 mg at 10 4 M). After pre-stimulation with 
10 5 M noradrenaline, acetylcholine reduced force of contraction in both tissues at 10 _3 M (atrium: -14_+ 4%, ventricle: 
-61  _+ 5%). The data indicate that, in atrial tissue, force of contraction can be affected by either positive or negative inotropic 
agents. However, in ventricular tissue only positive inotropic effects could be detected. Since atrial and ventricular tissues display 
different responses to the above biogenic substances, a different mechanism of regulation of contractility seems feasible. 
Key words: Acetylcholine; Adenosine; Angiotensin II; Atrium; Contractility; a-CGRP (calcitonin gene-related peptide); Somato- 
statin; Ventricle; (Human) 
1. Introduction 
In humans the /3-adrenoceptor-Gs-protein-adenyly l  
cyclase pathway is the most powerful  mechanism for 
the regulat ion of cardiac contracti l ity. By using either 
the same or alternat ive pathways, several other bio- 
genic substances can also affect cardiac contracti l ity, 
and hence, they may also be involved in the regulat ion 
of cardiac function. Substances that evoke positive 
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inotropic effects include 5-hydroxytryptamine (5-HT) 
(mediated by 5-HT 4 receptor;  Kaumann et al., 1991; 
Schoemaker  et al., 1993; Zerkowski  et al., 1993), his- 
tamine (mediated mainly by H 2 receptor;  Bristow et 
al., 1982; Duet  al., 1993; Zerkowski  et al., 1993), 
vasoactive intestinal pept ide (VIP) (mediated by VIP  
receptor;  Hershberger  et al., 1989), angiotensin II 
(mediated by angiotensin AT~ receptor;  Urata  et al., 
1989; Zerkowski  et al., 1993) and endothel in  (mediated 
by ET A receptor;  Brodde et al., 1992). Substances that 
evoke negative inotropic effects include adenosine 
(mediated by adenosine A~ receptor;  Hershberger  et 
al., 1987), somatostat in (mediated via somatostat in re- 
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ceptors; Hershberger et al., 1988), and acetylcholine 
(mediated by M, receptor; Brodde et al., 1992). 
It has been recently reported that 5-HT increases 
the atrial force of contraction without affecting the 
ventricular contraction in the pig (Saxena et aI., 1992; 
Schoemaker et al., 1992) as well as in humans (Jahnel 
ct al., 1992; Schoemaker et al., 1993), thus suggesting 
that an agent can elicit a positive inotropic response in 
the atrium without having a corresponding effect in the 
ventricles. In this investigation with human heart, we 
report similar characteristics of several other sub- 
stances - human calcitonin gene-related peptide 
(CGRP), angiotensin 1I, adenosine, somatostatin and 
acetylcholine. We focused on the comparison of the 
responses of atrial and ventricular tissues obtained, in 
most cases, from the same non-diseased human hearts. 
To our knowledge, this is the first study to investigate 
the contractile responses of atrial and ventricular tis- 
sues from the same heart in parallel. Part of this 
investigation has been presented at the winter meeting 
of the British Pharmacological Society (Duet  a[., 1994). 
2. Material and methods 
2.1. General preparations 
Right atrial and left ventricular trabeculae were 
obtained from 42 'beating heart' organ donors (27 
males, 15 females; age 1-54 years) who died of non- 
cardiac disorders (26 cerebrovascular ccident, 14 poly- 
trauma, 1 encephalopathy, 1 hypoxia) less than 24 h 
before the tissue was taken to the laboratory.. The 
hearts were kindly provided by the Rotterdam Heart 
Valve Bank (Bio Implant Services Foundat ion/Euro-  
transplant Foundation) after removal of the aortic and 
pulmonary valves for homograft valve implantation. 
The hearts were stored at 0-4°C in a sterile organ 
protecting solution (UW, Eurocollins, or HTK-Bret- 
tschneider; see Ploeg et al., 1992) immediately after 
circulatory arrest. 
After excision, pieces of atrial and ventricular my- 
ocardium were placed in ice-chilled oxygenated Krebs 
buffer (composition in mM: NaC1 118, KCI 4.7, CaC12 
2.5, MgSO 4 1.2, NaHCO.~ 25, KHPO 4 1.2 and glucose 
8.3) and atrial and ventricular trabeculae (<1 mm 
thickness) were carefully dissected free. The trabeculae 
were mounted in organ baths (gassed with 95% O 2 and 
5c7/~ CO,; 37°C) and then prepared for isometric ten- 
sion recording with a Harvard transducer. Resting ten- 
sion was set to 750 and 1950 mg for atrial and ventricu- 
far tissues, respectively, in order to provide optimal 
loading conditions. Tissues were paced at 1 Hz, using 
electrical field stimulation (3 ms, voltage 20% above 
threshold). 
2.2. f~2vperimental protocol 
After stabilization, ttle baseline fl)rcc of contraction 
was measured. A concentration-response curve for no- 
radrenaline was obtained to check the inotropic re- 
sponsiveness of the tissues. Since the tissues were 
irreversibly damaged after a concentration of It) 4 M 
(the baseline force of contraction decreased aftcr 
washout and did not recover in a reasonable time), the 
maximum concentration of noradrcnalinc was re- 
stricted to 10 5 M. The responses to all other stlb- 
stances are expressed as percentages of either the 
response to 10 5 M noradrenaline or the baselinc 
force of contraction. Tissues with a response to 10 " 
M noradrenaline smaller than 25 mg were excluded 
from further analysis. 
After the tissues had been washed (6 times) and had 
stabilized, a concentration-response curve tk)r CGRP 
(10 ~ to 10 : M), angiotensin II (10 '~ to 10 5 M), 
adenosine (10 s to 10 5 M), somatostatin (It) s to 
10 " M). or acetylcholine (10 '~ to lt) 3 M, in thc 
presence of 10 -s M physostigmine to prevent rapid 
degradatkm of acetylcholine by cholinesterase; sec 
Chatonnct and Lockridge, 1989)was obtained in paral- 
lel in both atrial and ventricular tissues. Only onc 
substance was studied per tissue. After another wash 
and stabilization perk)d, the concentration-response 
curve for adenosine and somatostatin was constructcd 
again following pre-stimulation with 10 > M nora- 
drenaline. Because of desensitization occurring after 
rcpeated exposure to acctylcholine, the above-de- 
scribed experiments with this substance lifter pre- 
stimulation with 10 5 M noradrenaline were carried 
out in separate tissues. At the end of each experiment 
without pre-stimulation with noradrenalinc (except in a 
few cases where the tissue was frozen for further 
investigations which are not reported here), another 
noradrcnaline concentration-responsc curve was ob- 
tained after washing and re-stabilization (at least 10 
min) to check the viability of the tissue. In the case of 
investigations with adenosine and acetylcholine in pre- 
stimulated (10 ~ M noradrenalinc) myocardium, wc 
checked the stability of the noradrcnalinc rcsponsc by 
administering 10 5 M noradrenalinc at the end of 
protocol. 
2.3. Data presentation and attalysis 
All data are presented as means _+_ S.E.M. Baseline 
values for atrial and ventricular tissues were compared 
by using an unpaired t-test. The effects of nora- 
drenaline, CGRP, angiotensin It, adenosine, somato- 
statin and acetylcholine were analyzed by using an 
analysis of variance (ANOVA) for repeated measure- 
ments. Differences were regarded statistically signifi- 
cant if P < 0.05. 
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2.4. Compounds used RIGHT ATRIUM 
The compounds used in the present study were: 
noradrenaline bitartrate (Sigma, St. Louis, MO, USA), 
adenosine (Janssen, Geel, Belgium), angiotensin II, 
human CGRP and somatostatin-14 (Saxon, Hannover, 
Germany), acetylcholine chloride (Ciba, Breda, Neth- 
erlands), atropine sulphate (Centrafarm, Etten-Leur, 
Netherlands), physostigmine salicylate (Sandoz, Basel, 
Switzerland) and propranolol hydrochloride (Imperial 
Chemical Industries, Macclesfield, UK). 
3. Results 
3.1. Viability of the tissues 
On average, the baseline force of contraction was 
significantly lower in atrial tissue (126 + 25 rag, n = 37) 
than in ventricular tissue (221 ± 34 mg, n = 34). In 
both tissues noradrenaline (10 s to 10 -5 M) increased 
force of contraction in a concentration-dependent 
manner. After exposure to 10 5 M noradrenaline, the 
force of contraction went up to 548 + 55 mg (n = 37) 
and 599 ± 78 mg (n = 34) in the atrial and ventricular 
trabeculae, respectively. When the response to nora- 
drenaline (10 -5 M) was elicited again at the end of the 
protocol, similar (in atrial trabeculae: 107 + 10% of the 
initial noradrenaline response, n = 33) or even greater 
(in ventricular trabeculae: 177 _+ 29% of the initial no- 
radrenaline response, n = 31) increases in force of 
contraction were observed. 
3.2. Positit,e inotropic effects 
3.2.1. CGRP 
An example of the recordings obtained from the 
atrial and ventricular trabeculae is shown in Fig. 1. 
Unlike noradrenaline, CGRP increased force of con- 
traction in atrial but not in ventricular tissue. The 
mean results are shown in Fig. 2 (left panel). CGRP 
(10 -9 to 10 -7 M) exerted a positive inotropic effect in 
a concentration-dependent manner in the atrial tissue. 
At 10 7 M CGRP, force of contraction increased 
significantly from 374 _+ 128 mg at baseline up to 545 ± 
151 rag, or 36 +_ 8% of the response to 10 -5 M nora- 
drenaline (n = 8). In contrast, no significant change 
was noticed in the ventricular force of contraction 
(baseline: 356_+ 73 rag, 10 7 M CGRP: 374_+ 79 mg, 
n = 8). 
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Fig. I. Recordings of force of contraction of a right atrial (top) and a 
left ventricular (bottom) trabecula showing the effects of cumulative 
concentrations of CGRP as compared to those of noradrenaline 
(NA), before and after CGRP. 
other 4 trabeculae (67%) showed an enhanced force of 
contraction, which increased from 70 +_ 50 mg at base- 
line to 398 + 117 mg with 10 .5 M angiotensin II (see 
Fig. 2, right panel). No response was seen in any of the 
5 ventricular trabeculae. 
3.3. Negatit~e inotropic effects 
3.3.1. Adenosine 
The effects of adenosine (10 ~ to 10 -5 M) on the 
atrial and ventricular force of contraction at baseline 
or in the presence of 10 5 M noradrenaline are pre- 
sented in Fig. 3. In the atrial tissue, adenosine signifi- 
cantly reduced baseline force of contraction (from 116 
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3.2.2. Angiotensin H
On average angiotensin II (10 -9 M to 10 -5 M) 
caused a concentration-dependent increase in the atrial 
force of contraction, but 2 out of 6 atrial trabeculae 
(33%) did not respond to angiotensin II. Data from the 
-Log [CGRP] -Log [Angiotensin II] 
Fig. 2. Cumulative concentration-response curves of CGRP and 
angiotensin II in atrial and ventricular trabeculae (CGRP: n = 8 
each; angiotensin II: n = 4 and 5 for atrium and ventricles, respec- 
tively). Responses to both compounds are expressed as percentages 
of the response to l(I 5 M noradrenaline (NA). 
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Fig. 3. Concentrat ion-response curves of adenosine on the basel ine 
force of contract ion (n = 6) and on the force of contraction after 
pre-st imulat ion with 10 -5 M noradrenal ine (NA; n = 5), obta ined 
with atrial and ventr icular tissues. 
+57 mg to 58,+40 mg at 10 5 M; n=5) ,  as well as 
force of contraction in the presence of 10 5 M nora- 
drenal ine (503 ,+ 134 mg to 317_+ 114 mg at 10 5 M; 
n = 6). In the ventricular tissue, adenosine did not 
affect baseline contractil ity (baseline: 86 +_ 30 rag, 10 5 
M adenosine: 93 _+ 30 rag; n = 5) and only slightly (but 
significantly) decreased force of contraction after pre- 
stimulation with 10 -5 M noradrenal ine (from 657 + 140 
mg down to 597_+ 137 rag, at 10 -5 M; n = 6). 
3.3.2. Somatostatin 
The mean results from 5 pairs of atrial and ventricu- 
lar trabeculae are shown in Fig. 4. Over a concentra- 
tion range of 10 s to 10 ~' M, somatostatin decreased 
the atrial baseline force of contraction from 464 + 184 
mgto  180 _+124 mg ( - 51__+ 25%) at 10 ~ M, but i td id  
not affect the atrial force of contraction after pre- 
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Fig. 4. Concentrat ion-response curves of somatostat in on the base- 
line force of contract ion (n = 5) and on the force of contract ion after 
pre-st imulat ion with 10 5 M noradrenal ine (NA; n = 5), obtained 
with atrial and ventr icular tissues. 
-Log [NA] -Log [ACh] 
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Fig. 5. Recordings of force of contraction of two right atrial (top 2 
panels) and two left ventricular (bottom 2 panels) trabeculae ob- 
tained from the same hearts. The recordings how the effects of 
cumulative concentrations of acetylcholine (in the presence of 1() ~ 
M physostigmine) on the baseline force of contraction (first and third 
panels) and after pre-stimulation with 10 s M noradrenaline (NA: 
second and fourth panels). For comparison, the sustained effect of 
stimulation with 10 5 M noradrenaline is also presented. 
stimulation with 10 ~ M noradrenal ine (928 + 83 mg 
before and 936 + 95 mg after 10 -~' M somatostatin). 
Neither at baseline nor after pre-stimulation with nora- 
drenal ine did somatostatin affect ventricular contractil- 
ity. 
3.4. Mixed inotropic effects o f  acetylcholine 
An example of recordings showing the effects of 
acetylcholine on the right atrial and left ventricular 
trabeculae is presented in Fig. 5. In the atrial trabec- 
ula, acetylcholine licited a biphasic effect, consisting 
of an initial negative inotropic response (from 10 ~ to 
10 -7 M) followed by a positive inotropic response 
(from 10 -~' to 10 4 M). It should be noted that even 
after the highest concentration of acetylcholine (10 ~ 
M) the force of contraction did not exceed the baseline 
value. In the ventricular trabecula, acetylcholine caused 
a clear concentrat ion-dependent positive inotropic ef- 
fect. After administration of 10 -5 M noradrenal ine.  
which resulted in a stable increase in the atrial and 
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Fig. 6. Concentration-response curves of acetylcholine on the base- 
line force of contraction and on the force of contraction after 
pre-stimulation with 10 5 M noradrenaline (NA) in atrial and ven- 
tricular tissues. The number of atrial and ventricular trabeculae used 
were 8 and 6, respectively, in the left panel; and 7 and 6, respectively, 
in the right panel. 
ventricular force of contraction, acetylcholine pro- 
duced only negative inotropic effects in both tissues. 
The mean results of the effects of acetylcholine on 
the atrial and ventricular baseline force of contraction 
are shown in Fig. 6 (left panel). In the atrial tissue, at 
low concentrations acetylcholine decreased baseline 
force of contraction from 120 + 41 mg to 48 + 16 mg 
( -50  + 11%) at 10 7 M (n -- 8), whereas in concentra- 
tions above 10 6 M, acetylcholine increased force of 
contraction (up to 77 _+ 15 mg at 10 -3 M; n = 8) back 
towards baseline values. In the ventricular tissue, 
acetylcholine increased baseline force of contraction in 
a concentration-dependent manner (maximal response 
358 +_ 70 mg or 56 +_ 16% increase from baseline at 
10 -5 M; n = 6). Fig. 6 (right panel) presents the mean 
results of the effects of acetylcholine on force of con- 
traction after pre-stimulation with 10 -5 M nora- 
drenaline. At 10 _3 M, acetylcholine reduced the atrial 
(n = 7) and ventricular (n = 6) force of contraction 
from 504 +_ 141 mg and 463 + 93 mg, respectively, to 
43 _+ 6 mg (14 +_ 4%) and 288 +_ 59 mg (61 + 5%), re- 
spectively. 
4. D iscuss ion  
Recent investigations have established that 5-HT, 
which increases heart rate and atrial contractility in 
both porcine (Saxena, 1986; Born et al., 1988; Kau- 
mann, 1990; Villaldn et al., 1990) and human (Kau- 
mann et al., 1990, 1991) heart by acting at 5-HT 4 
receptors, does not have a direct effect on ventricular 
contractility (Jahnel et al., 1992; Saxena et al., 1992; 
Schoemaker et al., 1992, 1993). Therefore, the main 
purpose of the present investigation was to establish 
whether or not such a differential effect is also noticed 
with other biogenic substances in atrial and ventricular 
trabeculae obtained from the same non-diseased hu- 
man heart. Since the adenylyl cyclase/cAMP pathway 
is the major system regulating force of cardiac contrac- 
tion (Brodde et al., 1992), noradrenaline was used to 
check the inotropic responsiveness and viability of the 
tissues, both at the beginning and at the end of the 
experiments. As in our previous studies (Du et al., 
1993; Schoemaker et al., 1993), tissues not responding 
to noradrenaline at the beginning of the experiment 
were rejected. All tissues responded to noradrenaline 
at the end of experiment, confirming that these tissues 
remained viable during the course of the experiment. 
4.1. Positice inotropic effects 
CGRP, a neuropeptide released by the endings of 
sensory nerve fibres, exerts a positive inotropic effect 
on atrial but not on ventricular myocardium of the rat 
(Sigrist et al., 1986; Ishikawa et al., 1987) and guinea-pig 
(Saito et al., 1987; Ishikawa et al., 1988; Giuliani et al., 
1992). In both species the atrial effect of CGRP is 
associated with an increase in cAMP (Sigrist et al., 
1986; Ishikawa et al., 1988). In the dog, CGRP (up to 1 
/xM) has no effect on either the atrial or ventricular 
trabeculae (Rigel et al., 1989). In the human my- 
ocardium, a positive inotropic effect has been reported 
on the atrial tissue (Franco-Cereda et al., 1987), but no 
data are available about the effect of CGRP on the 
ventricular contractility. Our results show that, similar 
to the rat and guinea-pig, a positive inotropic effect of 
CGRP was observed in human atrial trabeculae. How- 
ever, CGRP had no effect on ventricular tissue ob- 
tained from the same heart. As was the case with 5-HT 
(Schoemaker et al., 1993), the lack of effect of CGRP 
on the ventricular myocardium was not due to deterio- 
ration of the tissue during the experiment. Animal 
studies have shown that specific binding sites for CGRP 
can be identified in high concentration in the atrium 
(Sigrist et al., 1986), but such sites are scarce in the 
ventricles (Ishikawa et al., 1988). Therefore, a low 
receptor density may explain the lack of response in 
the ventricular muscle. 
As has been reported earlier (Urata et al., 1989; 
Moravec et al., 1990; Zerkowski et al., 1993), an- 
giotensin II did increase atrial contractility in our ex- 
periments, though not all atrial preparations re- 
sponded to this peptide. In addition, our experiments 
show that angiotensin did not affect human ventricular 
contractility. Though Moravec et al. (1990) reported 
that angiotensin II has a positive inotropic effect on 
human ventricular trabeculae, the responses in the 
atrium were more pronounced. The reason for this 
difference is not clear, but it may be related to the 
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heterogeneous receptor distribution in the human my- 
ocardium (Urata et al., 1989). The effects of an- 
giotensin II on atrial tissue are mediated by an- 
giotensin ATj receptors (Pieske et al., 1993; Zerkowski 
et al., 1993), which are coupled to the production of 
phospholipase C/diacylglycerol from inositol-l,4,5-tri- 
sphosphate (Brodde et al., 1992; Zerkowski et al., 
1993). This indicates that the discrepancy between 
atrial and ventricular contractile responsiveness is not 
restricted to adenylyl cyclase/cAMP-mediated mecha- 
nisms. 
4.2. Negatil,e inotropic effects 
Adenosine elicited a negatwe inotropic effect on the 
baseline as well as noradrenaline-stimulated atrial con- 
tractility, but it had no (baseline) or little (noradrena- 
line-stimulated) effect on ventricular contractility. 
Adenosine as well as some of its analogues have been 
shown to inhibit isoprenaline-stimulated force of con- 
traction in ventricular myocardium at concentrations 
above 10 5 M (B6hm et al., 1985; Jakob et al., 1989). 
The negative inotropic effect of adenosine seems to be 
mediated by A. receptors, which are negatively cou- 
pled to adenylyl cyclase and have been identified in 
both human atrial and ventricular myocardium (B6hm 
et al., 1985; Hershberger et al., 1987; Schmitz et al., 
1987). However, in human atrial tissue, the density of 
the A l receptors is about twice as high as in ventricular 
tissue (B6hm ct al., 1989), which could offer an expla- 
nation for the difference in the pharmacological re- 
sponses of the atrium and ventricle. 
Somatostatin exerted a concentration-dependent 
negative inotropie action on the baseline atrial force of 
contraction. No effect was noticed on the nora- 
drenaline-stimulated atrial trabeculae or on the ven- 
tricular trabeculae, with or without stimulation with 
noradrenaline, despite a report that somatostatin may 
inhibit adenylyl cyclase activity in the human ventricu- 
lar myocardium (Hershberger et al., 1988). Somato- 
statin is suggested to act via a receptor that is nega- 
tively coupled to the adenylyl cyclasc pathway via G~- 
proteins (Brodde et al., 1992). In atrial fibres, the 
inhibitory effect of somatostatin on contractility was 
associated with a reduction of intracellular calcium 
(Hou et al., 1987). The concentration of somatostatin 
in the atrioventricular node and right atria was found 
to be significantly higher than in other heart regions 
(Day et al., 1985), suggesting that somatostatin has a 
role in the cardiac conduction system rather than in 
the direct regulation of ventricle contractility. The lack 
of a negative inotropic effect on ventricular contractil- 
ity is apparently an optimistic sign from the point of 
the clinical use of somatostatin. Thus, for example, 
long-term (3-6 months) treatment with this drug has 
been reported to reverse left ventricular hypertrophy 
and improve exercise performance in acromegalic pa- 
tients (Tokg6zof~lu ct al., 1993). 
4.3. Mixed inotropic effects 
Acetylcholine caused a mixed positive and negative 
inotropic response in the present study. Both negative 
(at concentrations < 10 f' M) and positive (at concen- 
trations > 1(1 " M) inotropic effects of acetylcholine 
and other cholinergic agonists have been found in 
isolated atrial tissue from several animal species, in- 
cluding rabbit (Endoh and Blinks, 1984) and chick 
(Tajima et al., 1987), as well as rat and guinea-pig 
(Eglen et al., 1988). In ventricular tissue, only a posi- 
tive inotropic effect on baseline contractility (started at 
10 -~ M) and a negative inotropic effect (though weaker 
than in the atrial tissue) after pre-stimulation with 
noradrenaline were seen. The negative inotropic effect 
is consistent with findings reported in the literature 
(see Jakob et al., 1989); the effect depends on the 
presence of drugs that increase force of contraction by 
augmenting cellular cAMP (Korth and Kiihlkamp, 1987; 
L6ffelholz and Pappano, 1987). In most species, the 
positive inotropic effect of muscarinic agonists in ven- 
tricular tissues is only seen at concentrations above 
10 -5 M (Korth and Kiihlkamp, 1987: Tsuji et al., 1987). 
However, our results are consistent with a report by 
Gilmour and Zipes (1985) that acetylcholine licits a 
positive inotropic response at concentrations ranging 
from 10 ~ to 10 4 M in canine cardiac Purkinjc fibres. 
Both the positive and the negative inotropic effects 
could be antagonized by atropine (Du et al., unpub- 
lished observations), indicating the involvement of 
muscarinic receptors. In the human heart, M2-rece p- 
tors are predominantly present (Brodde et al., 1992) 
and these seem to exist in two different states (Brown 
and Brown, 1984): a high-affinity state associated with 
inhibition of adenylyl cyclase causing negative inotropy 
(Korth and Ktihlkamp, 1987; Eglen ct al., 1988: Broddc 
et al., 1992), and a low-affinity state, coupled to a 
pertussis toxin-insensitive G-protein to stimulate inosi- 
tol-l,4,5-trisphosphate hydrolysis (Poggioli et al., 1986; 
Tsuji et al., 1987: Eglen et al., 1988), causing positive 
inotropy. This hypothesis provides a good explanation 
for the biphasic response in atrial tissue. In ventricular 
tissue, these high- and low-affinity states might also 
exist, but in most species only the latter is expressed, so 
that acetylcholine has predominantly a positive in- 
otropic effect. 
In conclusion, data from the present study show that 
several endogenous substances (CGRP, angiotensin II, 
adenosine, somatostatin and acetylcholine) exhibit dif- 
ferent effects on atrial and ventricular contractility. In 
general, atrial tissue shows more marked responses 
than ventricular tissue. Although the effects and the 
mechanisms of the above substances arc different, in 
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the end these substances affect Ca 2+ influx. Fabiato 
(1982) has suggested that, in many mammalian species, 
the Ca2+-induced release of Ca 2+ is more developed in 
the atrium than in the ventricle. This implies that the 
atrium is more sensitive than the ventricle to sub- 
stances that modify Ca 2+ influx. Therefore, a low sen- 
sitivity to Ca2+-induced release of Ca 2+, as well as a 
lower density or absence of the involved receptors, may 
be responsible for the poor ventricular responses to 
these agents. The results of this study may help provide 
a better understanding of the physiology of atrial and 
ventricular contractility, as well as an important direc- 
tion for drug development. 
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